全文获取类型
收费全文 | 375598篇 |
免费 | 43914篇 |
国内免费 | 3211篇 |
专业分类
耳鼻咽喉 | 7246篇 |
儿科学 | 11066篇 |
妇产科学 | 6663篇 |
基础医学 | 32102篇 |
口腔科学 | 5713篇 |
临床医学 | 49055篇 |
内科学 | 93430篇 |
皮肤病学 | 10428篇 |
神经病学 | 37335篇 |
特种医学 | 15943篇 |
外国民族医学 | 13篇 |
外科学 | 75391篇 |
综合类 | 2753篇 |
现状与发展 | 73篇 |
一般理论 | 177篇 |
预防医学 | 23136篇 |
眼科学 | 8652篇 |
药学 | 16305篇 |
1篇 | |
中国医学 | 327篇 |
肿瘤学 | 26914篇 |
出版年
2024年 | 785篇 |
2023年 | 5807篇 |
2022年 | 3280篇 |
2021年 | 8142篇 |
2020年 | 8644篇 |
2019年 | 7000篇 |
2018年 | 12929篇 |
2017年 | 11273篇 |
2016年 | 12656篇 |
2015年 | 13524篇 |
2014年 | 22838篇 |
2013年 | 25820篇 |
2012年 | 22245篇 |
2011年 | 23022篇 |
2010年 | 19716篇 |
2009年 | 22592篇 |
2008年 | 21212篇 |
2007年 | 20306篇 |
2006年 | 22196篇 |
2005年 | 19476篇 |
2004年 | 17791篇 |
2003年 | 15565篇 |
2002年 | 15075篇 |
2001年 | 5503篇 |
2000年 | 4257篇 |
1999年 | 5035篇 |
1998年 | 6206篇 |
1997年 | 5486篇 |
1996年 | 5080篇 |
1995年 | 4793篇 |
1994年 | 3350篇 |
1993年 | 2963篇 |
1992年 | 2277篇 |
1991年 | 2256篇 |
1990年 | 1795篇 |
1989年 | 1866篇 |
1988年 | 1641篇 |
1987年 | 1422篇 |
1986年 | 1480篇 |
1985年 | 1356篇 |
1984年 | 1421篇 |
1983年 | 1280篇 |
1982年 | 1523篇 |
1981年 | 1349篇 |
1980年 | 1179篇 |
1979年 | 761篇 |
1978年 | 835篇 |
1977年 | 836篇 |
1976年 | 644篇 |
1975年 | 592篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Alexandros Karabetsos MD Dr ; George Karachalios MD Dr ; Paraskevoula Bourlinou RN Nurse ; Asimina Reppa RN Nurse ; Rozeta Koutri MD Dr ; Androniki Fotiadou MD Dr 《Headache》1997,37(1):12-14
The efficacy and safety of ketoprofen and paracetamol were compared for the treatment of acute migraine in a randomized, double-blind study of 64 patients. Thirty-four patients received ketoprofen 100 mg intramuscularly, and 30 patients received paracetamol 500 mg intramuscularly. Partial or complete relief of pain and other symptoms was achieved 15 to 20 minutes after administration in the ketoprofen group and within 35 minutes in the paracetamol group. Complete relief of pain was achieved within 30 to 40 minutes after ketoprofen in 28 patients (82.5%) compared to 5 patients (17.5%) in the paracetamol group. Six of the patients treated with ketoprofen needed a second dose for complete relief of pain during the 4-hour follow-up period. Side effects were rare and minimal. Our findings suggest that ketoprofen produced statistically significant benefit in the treatment of acute migraine. 相似文献
82.
83.
84.
85.
86.
87.
Fos Expression in the Rat Brain Following Vaginal-Cervical Stimulation by Mating and Manual Probing 总被引:4,自引:2,他引:2
Marc J. Tetel Michael J. Getzinger Jeffrey D. Blaustein 《Journal of neuroendocrinology》1993,5(4):397-404
Vaginal-cervical stimulation (VCS), provided by mating or manual probing, induces many reproductive behavioral and endocrine changes in female rats. These changes include an increase in lordosis duration, heat termination and pseudopregnancy. Electro-physiological and [14C]2-deoxy-D-glucose studies collectively show that neurons in the medial preoptic area, ventromedial hypothalamus and midbrain central gray respond to manual VCS. In the present study we immunocytochemically labeled brain sections for Fos, the protein product of the immediate early gene c-fos, to detect VCS-responsive neurons in hormone-primed animals receiving VCS by mating or manual probing. In Experiment 1, females receiving mounts and intromissions were compared to: 1) vaginally-masked females receiving mounts but no VCS, 2) females exposed to an intact anesthetized male or 3) females not exposed to males or the testing arena. Those animals receiving VCS showed a dramatic increase in the number of Fos-immunoreactive cells in the medial preoptic area, posterodorsal portion of the medial amygdala and bed nucleus of the stria terminalis, as well as the dorsomedial hypothalamus, ventromedial hypothalamus and midbrain central gray. These effects of VCS were confirmed in Experiment 2 in animals receiving manual vaginal-cervical probing. These findings extend previous electrophysiological and [14C]2-deoxy-D-glucose studies by providing evidence that additional brain areas respond to VCS by mating, as well as manual probing. 相似文献
88.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc. 相似文献
89.
Dr. Michael Gosland Pharm.D. Dr. Bert Lum Pharm.D. Dr. Julia Schimmelpfennig Pharm.D. Dr. James Baker Pharm.D. Dr Michael Doukas M.D. 《Pharmacotherapy》1996,16(1):16-39
Cisplatin in combination with other cytotoxic agents is the backbone for a potential cure of testicular germ cell neoplasms and is a critical factor in the substantial activity observed in the treatment of small cell lung cancer, bladder cancer, and ovarian germ cell tumors. Resistance to cisplatin at the onset of treatment or at relapse limits its curative potential, however. Laboratory studies using both cells selected for cisplatin resistance by exposure to sublethal concentrations and biopsy specimens from patients' tumors provide insights for the potential mechanisms of resistance. The mechanisms identified in vitro include a complex and wide array of related and unrelated pathways such as alterations in cellular drug transport, enhanced DNA repair dependent and independent of signal transduction pathways, and enhanced intracellular detoxification such as glutathione and metallothionein systems. Studies of these mechanisms have identified a number of agents with known potential for administration to humans and that reverse cisplatin resistance in vitro; for example, reversal of cellular accumulation defects by dipyridamole; inhibition of DNA repair by hydroxyurea, pentoxifylline, and novobiocin; inhibition of the glutathione system by ethacrynic acid and buthionine sulfoximine; and inhibition of signal transduction pathways by cyclosporine, tamoxifen, and calcium channel-blocking agents. Current phase I clinical trials are focusing on the most effective doses and schedules to administer these agents in combination with cisplatin. Initial uncontrolled trials in limited numbers of patients suggest that the addition of modulators of cisplatin has the potential to reverse resistance in patients previously failing therapy. Another promising avenue for circumventing cisplatin resistance is the development of noncross-resistant platinum analogs. 相似文献
90.